Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
n(1)-acetyl-n(2)-formyl-5-methoxykynuramine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intracerebroventricular, Topical
01
Overview
N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (AFMK) is a primary kynuramine metabolite of melatonin, produced through the oxidative pyrrole-ring cleavage of melatonin by enzymes such as indoleamine 2,3-dioxygenase (IDO) or non-enzymatic reactions with reactive oxygen species. AFMK is a potent antioxidant and broad-spectrum free radical scavenger that protects cells from oxidative stress and mitochondrial dysfunction. Research indicates it possesses anti-inflammatory, neuroprotective, and anti-proliferative properties, showing potential in treating Alzheimer's disease, acute pancreatitis, and skin disorders. It acts partly through signaling via melatonin receptors (MT1 and MT2) and serotonin receptors (5-HT3). AFMK also serves as a precursor to another bioactive metabolite, N(1)-acetyl-5-methoxykynuramine (AMK).
- Other names
- N1-acetyl-N2-formyl-5-methoxykynuramineN-1-acetyl-N2-formyl-5-methoxykynuramineN 1-acetyl-N2-formyl-5-methoxykynuramineAFMK
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on n(1)-acetyl-n(2)-formyl-5-methoxykynuramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on n(1)-acetyl-n(2)-formyl-5-methoxykynuramine.